These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 31730495)

  • 1. Isoform-specific NF1 mRNA levels correlate with disease severity in Neurofibromatosis type 1.
    Assunto A; Ferrara U; De Luca A; Pivonello C; Lombardo L; Piscitelli A; Tortora C; Pinna V; Daniele P; Pivonello R; Russo MG; Limongelli G; Colao A; Tartaglia M; Strisciuglio P; Melis D
    Orphanet J Rare Dis; 2019 Nov; 14(1):261. PubMed ID: 31730495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1.
    Warrington NM; Woerner BM; Daginakatte GC; Dasgupta B; Perry A; Gutmann DH; Rubin JB
    Cancer Res; 2007 Sep; 67(18):8588-95. PubMed ID: 17875698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-occurrence of neurofibromatosis type 1 and optic nerve gliomas with autosomal dominant polycystic kidney disease type 2.
    Peces R; Mena R; Martín Y; Hernández C; Peces C; Tellería D; Cuesta E; Selgas R; Lapunzina P; Nevado J
    Mol Genet Genomic Med; 2020 Aug; 8(8):e1321. PubMed ID: 32533764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative splicing of the neurofibromatosis type I pre-mRNA.
    Barron VA; Lou H
    Biosci Rep; 2012 Apr; 32(2):131-8. PubMed ID: 22115364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper.
    Rodriguez FJ; Ligon AH; Horkayne-Szakaly I; Rushing EJ; Ligon KL; Vena N; Garcia DI; Cameron JD; Eberhart CG
    J Neuropathol Exp Neurol; 2012 Sep; 71(9):789-94. PubMed ID: 22892521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mid-aortic syndrome with renovascular hypertension and multisystem involvement in a girl with familiar neurofibromatosis von Recklinghausen type 1.
    Petrak B; Bendova S; Seeman T; Klein T; Lisy J; Zatrapa T; Marikova T
    Neuro Endocrinol Lett; 2007 Dec; 28(6):734-8. PubMed ID: 18063929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth.
    Solga AC; Pong WW; Kim KY; Cimino PJ; Toonen JA; Walker J; Wylie T; Magrini V; Griffith M; Griffith OL; Ly A; Ellisman MH; Mardis ER; Gutmann DH
    Neoplasia; 2015 Oct; 17(10):776-88. PubMed ID: 26585233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optic glioma and precocious puberty in a girl with neurofibromatosis type 1 carrying an R681X mutation of NF1: case report and review of the literature.
    Kocova M; Kochova E; Sukarova-Angelovska E
    BMC Endocr Disord; 2015 Dec; 15():82. PubMed ID: 26666878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurological malignancies in neurofibromatosis type 1.
    Eoli M; Saletti V; Finocchiaro G
    Curr Opin Oncol; 2019 Nov; 31(6):554-561. PubMed ID: 31436563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients.
    Ars E; Kruyer H; Morell M; Pros E; Serra E; Ravella A; Estivill X; Lázaro C
    J Med Genet; 2003 Jun; 40(6):e82. PubMed ID: 12807981
    [No Abstract]   [Full Text] [Related]  

  • 11. A novel diagnostic method to detect truncated neurofibromin in neurofibromatosis 1.
    Esposito T; Piluso G; Saracino D; Uccello R; Schettino C; Dato C; Capaldo G; Giugliano T; Varriale B; Paolisso G; Di Iorio G; Melone MA
    J Neurochem; 2015 Dec; 135(6):1123-8. PubMed ID: 26478990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
    Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
    Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice.
    Brown JA; Emnett RJ; White CR; Yuede CM; Conyers SB; O'Malley KL; Wozniak DF; Gutmann DH
    Hum Mol Genet; 2010 Nov; 19(22):4515-28. PubMed ID: 20826448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations.
    Sharif S; Upadhyaya M; Ferner R; Majounie E; Shenton A; Baser M; Thakker N; Evans DG
    J Med Genet; 2011 Apr; 48(4):256-60. PubMed ID: 21278392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation.
    Daginakatte GC; Gianino SM; Zhao NW; Parsadanian AS; Gutmann DH
    Cancer Res; 2008 Dec; 68(24):10358-66. PubMed ID: 19074905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
    Gottfried ON; Viskochil DH; Couldwell WT
    Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.
    Diggs-Andrews KA; Brown JA; Gianino SM; Rubin JB; Wozniak DF; Gutmann DH
    Ann Neurol; 2014 Feb; 75(2):309-16. PubMed ID: 24375753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neurofibromin - protein structure and cellular functions in the context of neurofibromatosis type I pathogenesis].
    Abramowicz A; Gos M
    Postepy Hig Med Dosw (Online); 2015 Dec; 69():1331-48. PubMed ID: 26671924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation.
    Koczkowska M; Callens T; Gomes A; Sharp A; Chen Y; Hicks AD; Aylsworth AS; Azizi AA; Basel DG; Bellus G; Bird LM; Blazo MA; Burke LW; Cannon A; Collins F; DeFilippo C; Denayer E; Digilio MC; Dills SK; Dosa L; Greenwood RS; Griffis C; Gupta P; Hachen RK; Hernández-Chico C; Janssens S; Jones KJ; Jordan JT; Kannu P; Korf BR; Lewis AM; Listernick RH; Lonardo F; Mahoney MJ; Ojeda MM; McDonald MT; McDougall C; Mendelsohn N; Miller DT; Mori M; Oostenbrink R; Perreault S; Pierpont ME; Piscopo C; Pond DA; Randolph LM; Rauen KA; Rednam S; Rutledge SL; Saletti V; Schaefer GB; Schorry EK; Scott DA; Shugar A; Siqveland E; Starr LJ; Syed A; Trapane PL; Ullrich NJ; Wakefield EG; Walsh LE; Wangler MF; Zackai E; Claes KBM; Wimmer K; van Minkelen R; De Luca A; Martin Y; Legius E; Messiaen LM
    Genet Med; 2019 Apr; 21(4):867-876. PubMed ID: 30190611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.
    Dasgupta B; Yi Y; Chen DY; Weber JD; Gutmann DH
    Cancer Res; 2005 Apr; 65(7):2755-60. PubMed ID: 15805275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.